Pharma Deals Review, Vol 2004, No 48 (2004)

Font Size:  Small  Medium  Large

Watson Licenses North American Rights to Silodosin from Kissei

Business Review Editor

Abstract


Kissei granted Watson, the exclusive rights to develop and commercialise KMD-3213 (silodosin) in North America. KMD-3213 is used in the treatment of benign prostatic hyperplasia.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.